Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink

Group 1 - Leerink raised the price target on Vertex Pharmaceuticals (VRTX) to $525 from $456, maintaining an Outperform rating on the shares [1] - The increase in the price target is attributed to a rise in the terminal growth assumption from 1% to 2% [1] - Leerink expresses optimism regarding the company's revenue and pipeline prospects, which are expected to positively influence stock price performance [1] Group 2 - The firm projects higher investment spending growth than consensus models, indicating a more aggressive growth outlook [1]